180,087 Shares in Haleon PLC Sponsored ADR $HLN Purchased by Park Avenue Securities LLC

Key Points

• Park Avenue Securities LLC acquired a significant stake of 180,087 shares in Haleon PLC, valued at approximately $1.87 million.
• The company recently declared a semi-annual dividend of $0.0555, reflecting a yield increase from its previous dividend.
• Analysts have mixed views on Haleon, with ratings ranging from Strong Buy to Hold, and an average target price set at $12.33.

Park Avenue Securities LLC acquired a new stake in shares of Haleon PLC Sponsored ADR (NYSE:HLN - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 180,087 shares of the company's stock, valued at approximately $1,867,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Bartlett & CO. Wealth Management LLC raised its position in shares of Haleon by 135.9% in the first quarter. Bartlett & CO. Wealth Management LLC now owns 2,588 shares of the company's stock valued at $27,000 after purchasing an additional 1,491 shares during the period. Banque Transatlantique SA bought a new stake in Haleon during the 1st quarter valued at $27,000. Opal Wealth Advisors LLC purchased a new stake in shares of Haleon during the first quarter worth $29,000. Ransom Advisory Ltd purchased a new stake in shares of Haleon during the first quarter worth $31,000. Finally, Deutsche Bank AG boosted its holdings in shares of Haleon by 267.8% in the first quarter. Deutsche Bank AG now owns 3,126 shares of the company's stock worth $32,000 after acquiring an additional 2,276 shares during the period. Institutional investors own 6.67% of the company's stock.

Haleon Stock Performance

NYSE:HLN opened at $8.88 on Thursday. The stock has a market cap of $39.74 billion, a P/E ratio of 22.77, a PEG ratio of 2.64 and a beta of 0.24. The company has a quick ratio of 0.63, a current ratio of 0.87 and a debt-to-equity ratio of 0.48. The business's 50-day moving average price is $9.61 and its two-hundred day moving average price is $10.14. Haleon PLC Sponsored ADR has a twelve month low of $8.86 and a twelve month high of $11.42.

Haleon Increases Dividend

The business also recently declared a semi-annual dividend, which was paid on Thursday, September 18th. Shareholders of record on Friday, August 15th were paid a $0.0555 dividend. The ex-dividend date of this dividend was Friday, August 15th. This represents a yield of 190.0%. This is a boost from Haleon's previous semi-annual dividend of $0.05. Haleon's dividend payout ratio is presently 28.21%.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Barclays lowered Haleon from an "overweight" rating to an "equal weight" rating in a research note on Tuesday, September 16th. Wall Street Zen lowered Haleon from a "buy" rating to a "hold" rating in a report on Saturday, July 12th. Finally, The Goldman Sachs Group raised shares of Haleon from a "neutral" rating to a "buy" rating in a report on Wednesday, September 10th. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and five have issued a Hold rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $12.33.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.